Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahabadi Mostafa, Norouzi Mehdi, Alavian Seyed Moayyed, Samimirad Katayoon, Azad Talat Mokhtari, Saberfar Esmaeil, Mahmoodi Mahmood, Ramezani Fatemeh, Karimzadeh Hadi, Malekzadeh Reza, Montazeri Ghodrat, Nejatizadeh Azim, Ziaee Masood, Abedi Farshid, Ataei Behrooz, Yaran Majid, Sayad Babak, Hossein Somi Mohammad, Sarizadeh Gholamreza, Sanei-Moghaddam Ismaeil, Mansour-Ghanaei Fariborz, Rafatpanah Houshang, Pourhosseingholi Mohammad Amin, Keyvani Hossain, Kalantari Ebrahim, Saberifiroozi Mehdi, Ali Judaki Mohammad, Ghamari Shiva, Daram Maryam, Fazeli Zeinab, Goodarzi Zahra, Khedive Abolfazl, Moradi Abdolvahab, Jazayeri Seyed Mohamad
Аннотация
OBJECTIVES: The aim of this study was to characterize the hepatitis B virus reverse transcriptase (RT) protein variations among Iranian chronic HBV carriers who did not receive any antiviral treatments.
MATERIALS AND METHODS: Hepatitis B virus partial RT genes from 325 chronic in active carrier patients were amplified and directly sequenced. Nucleotide/amino acid substitutions were identified compared to the sequences obtained from the database.
RESULTS: All strains belonging to genotype D.365 amino-acid substitutions were found. Mutations related to lamivudine, adefovir, telbivudine, and entecavir occurred in (YMDD) 4% (n = 13), (SVQ) 17.23% (n = 56), (M204I/V + L180M) 2.45% (n = 8) and (M204I) 2.76% (n = 9) of patients, respectively.
CONCLUSIONS: RT mutants do occur naturally and could be found in HBV carriers who have never received antiviral therapy. However, mutations related to drug resistance in Iranian treatment-naïve chronic HBV patients were found to be higher than other studies published formerly. Chronic HBV patients should be monitored closely prior the commencement of therapy to achieve the best regimen option.